Tag
NASDAQ: AMGN
- Lilly reports 14.5‑month response duration with olomorasib lung-cancer combination
- Alvotech gains FDA approval for second SIMLANDI production suite
- Merck and Daiichi Sankyo withdraw ifinatamab deruxtecan BLA
- Amgen says dazodalibep met Phase 3 Sjögren's endpoint
- Scribe Therapeutics develops one‑time cholesterol treatment without permanent gene editing
- Can Quantinuum program Helios transform enterprise quantum computing?
- Against the rise of early onset cancer: a Mugglehead roundup
- Five startups taking aim at cancer diagnosis and treatment
- Why are Viridian Therapeutics shares on the rise on Tuesday?
- Vivos Therapeutics new device could provide substantial relief for migraine sufferers